Sunitinib and everolimus in pancreatic neuroendocrine tumors

Tumori

Volumn 98, Issue 3, 2012, Pages 394-

  Procopio, Giuseppe ^a   Pusceddu, Sara ^a   Buzzoni, Roberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PLACEBO; SUNITINIB;

ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; DRUG RESPONSE; FEASIBILITY STUDY; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LETTER; METABOLIC DISORDER; NEUTROPENIA; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DISEASE; STOMATITIS;

ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; HYPERTENSION; INDOLES; NEUROENDOCRINE TUMORS; NEUTROPENIA; PANCREATIC NEOPLASMS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; STOMATITIS; TREATMENT OUTCOME;

EID: 84867063288     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800319     Document Type: Letter

References (6)

1. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med, 326: 519-523, 1992.
2. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol, 29: 934-943, 2011.
3. Rinke A, Ricci S, Bajetta E, Jelic S: Pharmacological therapy of neuroendocrine tumors. Tumori, 96: 847-857, 2010.
4. Della Torre S, Procopio G, Fusi A, Catena L, Ferrari L, Nova P, Denaro A, Bichisao E, Bajetta E: Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy. Tumori, 89: 111-116, 2003. (Pubitemid 36745210)
5. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 364: 501-513, 2011.
6. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 364: 514-523, 2011.